Cytisinicline + Placebo
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Smoking Cessation
Conditions
Smoking Cessation
Trial Timeline
Oct 13, 2020 → Dec 23, 2021
NCT ID
NCT04576949About Cytisinicline + Placebo
Cytisinicline + Placebo is a phase 3 stage product being developed by Achieve Life Sciences for Smoking Cessation. The current trial status is completed. This product is registered under clinical trial identifier NCT04576949. Target conditions include Smoking Cessation.
What happened to similar drugs?
17 of 20 similar drugs in Smoking Cessation were approved
Approved (17) Terminated (0) Active (3)
Hype Score Breakdown
Clinical
17
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07392125 | Phase 3 | Recruiting |
| NCT05431387 | Phase 2 | Completed |
| NCT05206370 | Phase 3 | Completed |
| NCT04576949 | Phase 3 | Completed |
Competing Products
20 competing products in Smoking Cessation